ClinicalTrials.gg
CompletedNCT03755778Updated Jun 14, 2019

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

A Phase 1 interventional study of EDP-938 and EDP-938 in RSV Infection, sponsored by Enanta Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-14.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jan 2019, 7 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections — 1 open to participants now, 1 under way, none of them phase 3. EDP-938 · Respiratory Syncytial Virus Infections.

Enrollment
6th of 10
72 · median 81
Started
2018
with 2 others
Phase 1
6 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
10 of 10
Enanta Pharmaceuticals, Inc

Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, this one is the 6th largest by enrollment, is one of 3 that started in 2018, is one of 6 in phase 1, and was the 4th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About EDP-938

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects

03

Conditions studied

  • RSV Infection

Keywords

  • drug-drug interaction
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An document signed and dated by the subject.
  • Healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive.
  • Screening (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50 kg
  • Female subjects of must agree to use two effective methods of from the date of Screening until 90 days after the last dose of EDP 938.

Exclusion criteria

Exclusion Criteria:

  • evidence or history of illness or disease.
  • For Part 3 subjects, the following cardiovascular abnormalities:

    • QRS duration >110 ms
    • Incomplete right bundle branch block or any complete bundle branch block
    • Heart rate \<40 or >90 beats per minute (per vital sign capture while rested)
    • History of unexplained syncope, structural heart disease, or clinically significant arrhythmias
    • Personal or family history of long syndrome (genetically proven or suggested by sudden death of a close relative due to cardiac causes at a young age) or Brugada syndrome
    • PR interval >220 ms or any 2nd or 3rd degree AV block
    • Ventricular pre-excitation
  • Pregnant or nursing females.
  • History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
  • A positive urine drug screen at Screening or Day -1.
  • Current tobacco smokers or use of tobacco within 3 months prior to Screening.
  • Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).
  • History of regular alcohol consumption.
  • Participation in a clinical trial within 30 days prior to the first dose of study drug.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    EDP-938 and itraconazole interaction (Part 1)

    Drug: EDP-938 · Drug: Itraconazole

  • Experimental
    EDP-938 and rifampin interaction (Part 2)

    Drug: EDP-938 · Drug: Rifampin

  • Experimental
    EDP-938 and quinidine interaction (Part 3)

    Drug: EDP-938 · Drug: Quinidine

Interventions

  • Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)

  • Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)

  • Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)

  • Subjects will receive itraconazole once daily from Day 5 to Day 18

  • Subjects will receive rifampin once daily from Day 5 to Day 16

  • Subjects will receive quinidine once daily from Day 5 to Day 12

06

What researchers measure

Primary outcomes

  1. Cmax of EDP-938 with and without coadministration with itraconazole

    Time frame: Up to 19 days

  2. AUC of EDP-938 with and without coadministration with itraconazole

    Time frame: Up to 19 days

  3. Cmax of EDP-938 with and without coadministration with rifampin

    Time frame: Up to 17 days

  4. AUC of EDP-938 with and without coadministration with rifampin

    Time frame: Up to 17 days

  5. Cmax of EDP-938 with and without coadministration with quinidine

    Time frame: Up to 13 days

  6. AUC of EDP-938 with and without coadministration with quinidine

    Time frame: Up to 13 days

Secondary outcomes

  1. Safety measured by adverse events

    Time frame: Up to 25 days

07

Study locations

1 site
  • Pharmaceutical Research Associates, Inc.,
    Lenexa, Kansas 66219, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jan 2019, 1 month.

Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 1 month is below that.

Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2018
First posted
Nov 28, 2018
StartActual
Nov 29, 2018
Primary completionActual
Jan 21, 2019
CompletionActual
Jan 27, 2019
Last update
Jun 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03755778
Collaborators
Pharmaceutical Research Associates
Responsible party
Sponsor
First posted
Nov 28, 2018
Start date
Nov 29, 2018
Primary completion
Jan 21, 2019
Completion
Jan 27, 2019
Last update
Jun 14, 2019

Study contacts

Enanta Pharmaceuticals
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-938

Start the discussion